• Population PK/PD of Vernakalant in Atrial Fibrillation

  2026-09-03

  The reference study integrated population pharmacokinetic and pharmacodynamic data from five clinical trials to connect vernakalant exposure with QTcF and systolic blood pressure responses in atrial fibrillation or atrial flutter. Its conversion-status-aware models clarify why cardiac safety effects should be interpreted alongside baseline hemodynamics and treatment response rather than from plasma concentration alone.

• SB-505124 Hydrochloride Experimental Workflows

  2026-09-03

  Build reproducible TGF-β, fibrosis, and mechanobiology assays with SB-505124 hydrochloride, a reversible ALK4/5/7 inhibitor suited to pathway dissection. The workflow connects Smad2/3 target engagement with fibroblast activation, delivery studies, and carefully bounded cancer-cell stiffness experiments.

• LC-MS/MS Metabolomics of Carbapenemase Resistance

  2026-09-02

  A 2025 study used LC-MS/MS profiling of intracellular and extracellular metabolites to distinguish carbapenemase-producing Enterobacterales from non-producing isolates without antibiotic exposure. Twenty-one metabolite biomarkers and supervised machine-learning models separated the groups with AUROCs of at least 0.845, supporting development of faster resistance-detection assays.

• RIPA Lysis Buffer (Strong) for Cardiac Protein Studies

  2026-09-02

  Build reproducible cardiac protein extraction workflows for sepsis and inflammation studies with a strong detergent system designed for animal tissues and cultured cells. This guide connects sample handling, inhibitor strategy, Western blot and immunoprecipitation decisions, and troubleshooting to the lymphatic-protection findings reported in sepsis-induced cardiomyopathy.

• SIRT1/2 Inhibitor IV: Assay Workflows

  2026-09-01

  SIRT1/2 Inhibitor IV (cambinol) provides a cell-permeable way to perturb SIRT1/2 activity while tracking acetylation, lactylation, nuclear transport, and phenotype. This guide translates its established cancer-research uses into controlled CNS-injury and metabolic-pathway assays without treating a dual inhibitor as a SIRT1-specific probe.

• MDL 28170: A Practical Calpain Inhibitor Workflow

  2026-09-01

  MDL 28170 combines nanomolar calpain and cathepsin B inhibition with cell permeability and blood-brain barrier access, making it useful for mechanistic neuroprotection research rather than endpoint-only cytotoxicity testing. This guide translates a recent maternal-surgery neurodevelopment study into practical assay design, controls, optimization steps, and cross-domain applications.

• HyperScript™ Reverse Transcriptase for RNA Validation

  2026-08-31

  HyperScript™ Reverse Transcriptase supports structurally challenging RNA to cDNA conversion, long-template work, and cDNA synthesis for qPCR. This article shows how enzyme selection can improve interpretation of adaptive transcriptomic biology, using IP3 receptor knockout cells as a measurement-focused case study.

• Rhodamine 123 (chloride): Assay Guide

  2026-08-31

  A scenario-based guide to using Rhodamine 123 (chloride), SKU C3140, for P-glycoprotein efflux assays and membrane transport analysis. It covers formulation, controls, protocol optimization, interpretation limits, and practical vendor-selection criteria.

• Purmorphamine Workflows for Smoothened Signaling

  2026-08-30

  Purmorphamine is a practical Smoothened agonist for linking Hedgehog pathway activation to osteogenic, sensory, and exploratory neural assays. This guide translates receptor-level evidence into dose planning, workflow controls, and troubleshooting strategies for reproducible experiments.

• Making mRNA Delivery Measurable

  2026-08-29

  Translational mRNA research increasingly depends on separating delivery, intracellular localization, and protein expression rather than treating fluorescence as a single endpoint. This thought-leadership perspective connects the mechanistic lessons of targeted mRNA nanoparticles in ischemic stroke with a practical dual-readout strategy using ARCA Cy5 EGFP mRNA (5-moUTP).

• FPH1 (BRD-6125) Hepatocyte Workflow Guide

  2026-08-28

  FPH1 (BRD-6125) supports a function-first strategy for expanding primary human hepatocytes and improving iPSC-derived hepatocyte-like cells. This guide translates the product profile into practical dosing, assay design, troubleshooting, and a carefully bounded connection to light-regulated gene-expression research.

• mCherry mRNA for Nanoparticle Assay Design

  2026-08-28

  Learn how mCherry mRNA can function as more than a fluorescent reporter: it can help separate nanoparticle loading, cellular uptake, translation, and transcript persistence. This practical framework highlights how EZ Cap™ mCherry mRNA supports reproducible delivery and formulation decisions.

• Meropenem Trihydrate in Resistance Research

  2026-08-27

  Learn how Meropenem trihydrate supports reproducible susceptibility testing, resistance phenotyping, and metabolomics-informed assay design. This workflow-focused guide connects a broad-spectrum carbapenem antibiotic to practical controls, sample-handling decisions, and troubleshooting for bacterial infection treatment research.

• N-MYC–eIF4G1 Axis in inv(16) AML

  2026-08-27

  A 2024 Science Advances study identifies an essential MYCN enhancer and establishes the N-MYC/eIF4G1 pathway as a survival circuit in inv(16) acute myeloid leukemia. Its combined pharmacologic, transcriptional, functional, and patient-derived xenograft evidence clarifies how CBFβ-SMMHC-associated signaling sustains leukemia and suggests measurable endpoints for acute myeloid leukemia research.

• Cas9 mRNA–gRNA Delivery for LGMN Editing

  2026-08-26

  This Scientific Reports study developed a lipid nanoparticle strategy for co-delivering Cas9 mRNA and guide RNA to edit the metastasis-associated LGMN gene in breast cancer models. Its findings connect transient RNA-based genome editing with impaired lysosomal function and reduced cancer-cell migration and invasion, while also identifying practical considerations for guide-RNA and Cas9 mRNA production.

8018 records 1/535 page Next 12345 下5页 Last page